AstraZeneca complete acquisition
of site for new global HQ
Global pharmaceutical giant AstraZeneca completed the acquisition of its site at Cambridge Biomedical Campus following grant of detailed planning permission for the first phase of its 80,000 sq. m. HQ and research facility. The company has already begun the relocation of staff from locations across the UK and is making a major impact on the life sciences cluster in Cambridge, arguably now the leading technology cluster in Europe.